ImmunityBio (IBRX) Cash from Investing Activities (2014 - 2026)

ImmunityBio (IBRX) has reported Cash from Investing Activities for 13 consecutive years, with -$31.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 866.53% year-over-year to -$31.6 million; the TTM figure through Mar 2026 stood at -$185.6 million (down 774.71% YoY), while the FY2025 annual figure was -$149.8 million, down 1123.26% from the prior year.
• Cash from Investing Activities fell to -$31.6 million in Q1 2026 per IBRX's latest filing, from $43.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $116.7 million in Q2 2022 and bottomed at -$181.4 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$11.6 million across 5 years, with a median of -$8.6 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 1012.33% — and 2023, when it tumbled 1238.27%.
• ImmunityBio's Cash from Investing Activities stood at -$18.9 million in 2022, then jumped by 111.9% to $2.2 million in 2023, then jumped by 337.26% to $9.8 million in 2024, then surged by 343.09% to $43.6 million in 2025, then plunged by 172.64% to -$31.6 million in 2026.
• Business Quant data shows IBRX's Cash from Investing Activities at -$31.6 million in Q1 2026, $43.6 million in Q4 2025, and -$181.4 million in Q3 2025.